BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.
BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company reached on September 17th.
Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.
German pharmaceutical company BioNTech has agreed to pay a combined sum of more than $1.2 billion to resolve separate ...
DPA International on MSN4d
BioNTech and Pfizer to pay Covid-19 vaccine settlements in USThe German pharmaceutical company BioNTech announced on Friday that it has reached settlements in the US to resolve a ...
Seeking Alpha on MSN4d
BioNTech inks $1B settlements with NIH and Penn to resolve COVID vaccine royalty claimsBioNTech (BNTX) stock slipped after signing $1B deals with NIH and the University of Pennsylvania to resolve COVID vaccine ...
BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.
Pharma majors like BioNTech in Germany and Pfizer in the United States have made profits in billions of dollars in selling ...
BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback